Side-effects analysis gives Merck's new hep C med Zepatier an edge over older drugs

Merck & Co.'s ($MRK) hep C combo Zepatier has just hit the market, but the drug is already winning kudos for its side-effects profile. In a new analysis of clinical trial data, Zepatier turned up proportionally fewer serious side effects than Gilead Sciences' ($GILD) hep C combo treatment Harvoni and its veteran hep C med Sovaldi. Overall, Advera Health Analytics' report deemed Zepatier safer than Sovaldi and on par with Harvoni. More from FiercePharmaMarketing

Read more on